Clinical Trial Results:
The effect of naloxone and methylnaltrexone on oesophageal sensitivity in healthy volunteers: a randomized, double-blind placebo controlled study.
Summary
|
|
EudraCT number |
2012-003409-86 |
Trial protocol |
BE |
Global end of trial date |
18 Dec 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Feb 2021
|
First version publication date |
04 Feb 2021
|
Other versions |
|
Summary report(s) |
Thesis manuscript |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Methnalox2012
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03014843 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
KULeuven UZLeuven
|
||
Sponsor organisation address |
Herestraat 49, Leuven, Belgium, 3000
|
||
Public contact |
KU Leuven, TARGID, 32 16344225, jan.tack@kuleuven.be
|
||
Scientific contact |
KU Leuven, TARGID, 32 16344225, jan.tack@kuleuven.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Sep 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
18 Dec 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
18 Dec 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate the acute effect of naloxon and methylnaltrexone administered IV/SC on oesophageal sensitivity in healthy volunteers
|
||
Protection of trial subjects |
The identification of trial subjects was protected by using an identification code.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Oct 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
12
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
- | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Healthy volunteers were recruited | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Single blind | ||||||||||||
Roles blinded |
Subject | ||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||
Arm title
|
Methylnaltrexone subcutaneous + placebo infusion | ||||||||||||
Arm description |
Methylnaltrexone (12mg/0.6mL subcutaneous injection) + infusion of placebo (NaCl 0.9%) | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Methylnaltrexone
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
12mg/0.6mL methylnaltrexone
|
||||||||||||
Investigational medicinal product name |
Saline solution
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
0.9% NaCL via infusion
|
||||||||||||
Arm title
|
Placebo subcutaneous + naloxone infusion | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Saline solution
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
0.9% NaCL subcutaneous
|
||||||||||||
Investigational medicinal product name |
Naloxone
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for infusion
|
||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||
Dosage and administration details |
0.4mg IV bolus injection followed by 20µg/kg/h IV infusion
|
||||||||||||
Arm title
|
Placebo subcutaneous + placebo infusion | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Placebo | ||||||||||||
Investigational medicinal product name |
Saline solution
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||||||||
Routes of administration |
Intravascular use , Subcutaneous use
|
||||||||||||
Dosage and administration details |
0.9% NaCl injected subcutaneous and infused intravascular
|
||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Methylnaltrexone subcutaneous + placebo infusion
|
||
Reporting group description |
Methylnaltrexone (12mg/0.6mL subcutaneous injection) + infusion of placebo (NaCl 0.9%) | ||
Reporting group title |
Placebo subcutaneous + naloxone infusion
|
||
Reporting group description |
- | ||
Reporting group title |
Placebo subcutaneous + placebo infusion
|
||
Reporting group description |
- |
|
|||||||||||||||||
End point title |
Change in mechanical stimulation between methylnaloxone, naloxone and placebo | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Comparison between 3 conditions
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Mechanical stimulation ANOVA | ||||||||||||||||
Comparison groups |
Placebo subcutaneous + placebo infusion v Methylnaltrexone subcutaneous + placebo infusion v Placebo subcutaneous + naloxone infusion
|
||||||||||||||||
Number of subjects included in analysis |
36
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.33 | ||||||||||||||||
Method |
ANOVA | ||||||||||||||||
Confidence interval |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
For each individual, corresponds to timeframe of study participation (from signing of informed consent untill last visit)
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
23
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Headache and hunger was recorded during the experiment in some subjects. These non-serious adverse events are to be expected since the subjects needed to be fasted for this study. These symptoms were not regareded as adverse events. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Small number of subjects included in this study. Technical problems leading to unreliable data for some measurable variables for some subjects. |